SCHEMBL142474

SCHEMBL142474

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4ccccc4)cc32)c(C)c1CC(=O)N1CCN(C)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 6/20 0.55
SRC P12931 7/20 0.54
KDR P35968 10/20 0.53
FGFR1 P11362 9/20 0.53
PTK2B Q14289 3/20 0.53
MEN1 O00255 2/20 0.53
CDK2 P24941 2/20 0.53
KMT2A Q03164 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
CCNE1 P24864 1/20 0.53
RECQL P46063 1/20 0.53
PDGFRB P09619 8/20 0.53
EGFR P00533 2/20 0.53
AURKA O14965 3/20 0.51
LCK P06239 4/20 0.48
RET P07949 4/20 0.48
FLT3 P36888 3/20 0.48
MAP4K2 Q12851 3/20 0.48
STK3 Q13188 3/20 0.48
AURKB Q96GD4 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL141465 0.92 FGFR1 (0.52) METSRCKDRFGFR1PTK2B
SCHEMBL145230 0.92 MET (0.52) METSRCKDRFGFR1PTK2B
SCHEMBL146268 0.90 SRC (0.60) METSRCKDRFGFR1PTK2B
SCHEMBL147758 0.88 KDR (0.51) METSRCKDRFGFR1PTK2B
SCHEMBL144133 0.87 KDR (0.63) METSRCKDRFGFR1PTK2B
SCHEMBL142117 0.83 MET (0.63) METSRCKDRFGFR1PTK2B
SCHEMBL6516863 0.82 FGFR1 (0.68) METSRCKDRFGFR1PTK2B
SCHEMBL147260 0.82 FGFR1 (0.76) METSRCKDRFGFR1PDGFRB
SCHEMBL147370 0.82 KDR (0.60) METSRCKDRFGFR1PTK2B
SCHEMBL145990 0.82 MET (0.53) METSRCKDRFGFR1PTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed
WO-2005065686-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) 2005-07-21 WO disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US disclosed
WO-2002096361-A2 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 MET 310/4885SRC 2611/4885KDR 1077/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 MET 310/4885SRC 2611/4885KDR 1077/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 MET 151/4885SRC 75/4885KDR 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.